Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Unicycive Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for kidney diseases with significant unmet medical need. The company operates within the biotechnology and pharmaceuticals industry, with a primary emphasis on chronic and acute renal conditions. Its business model centers on advancing proprietary drug candidates through clinical development and, if approved, commercializing them directly or through strategic partners.
The company’s primary value driver is its lead product candidate oxylanthanum carbonate (OLC), being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD), including those on dialysis. Unicycive positions OLC as a next-generation phosphate binder designed to reduce pill burden compared with existing therapies. The company was founded in 2016 and is headquartered in Los Altos, California, evolving from a development-stage enterprise into a publicly traded company listed on NASDAQ (UNCY) through a reverse merger completed in 2018.
Business Operations
Unicycive operates as a single-reportable-segment company focused on drug development for renal and related metabolic diseases. Its operations are centered on clinical development, regulatory strategy, intellectual property management, and preparation for potential commercialization. The company does not currently generate product revenue and relies primarily on equity financing to fund operations.
The company controls development rights to oxylanthanum carbonate (OLC), which it licensed from Takeda Pharmaceutical Company Limited (through its Shire subsidiary, based on public disclosures). Unicycive also holds rights to UNI-494, a proprietary prodrug of niclosamide being explored for acute kidney injury and other inflammatory conditions, though clinical development remains at an earlier stage. As of publicly available filings, the company does not report material revenue-generating subsidiaries or joint ventures; operational activities are largely managed internally with the support of contract research organizations.
Strategic Position & Investments
Unicycive’s strategic direction is focused on advancing OLC toward regulatory approval in the United States, positioning it as a differentiated therapy in the phosphate binder market by emphasizing reduced pill burden and patient adherence. The company’s near-term growth strategy is heavily tied to clinical trial execution, regulatory engagement with the U.S. Food and Drug Administration, and potential commercialization planning.
Investment activity has primarily taken the form of internal R&D spending rather than acquisitions. The company has not disclosed ownership of a broad portfolio of subsidiaries or external operating businesses. Its pipeline strategy emphasizes renal-focused therapeutics, leveraging reformulation and prodrug technologies to improve existing treatment paradigms. Any expansion into additional indications or partnerships beyond kidney disease has not been conclusively verified in public sources.
Geographic Footprint
Unicycive Therapeutics is headquartered in North America, with its principal executive offices in Los Altos, California. The company’s operational footprint is concentrated in the United States, where its clinical development, regulatory interactions, and corporate governance are primarily based.
While clinical trials may involve international sites through third-party research organizations, the company does not report significant owned facilities or commercial operations outside the United States. International market presence and commercialization plans outside North America remain dependent on future regulatory approvals and partnership strategies, and publicly available information on long-term global expansion is limited.
Leadership & Governance
Unicycive is led by an executive team with experience in biotechnology development, clinical research, and capital markets. The leadership emphasizes a strategy centered on capital discipline, regulatory execution, and targeted innovation in kidney disease therapeutics, as reflected in corporate communications and public filings.
Key executives include:
- Shalabh Gupta, MD – Chief Executive Officer
- James P. Sapirstein – President and Chief Financial Officer
- Richard J. Russell, PhD – Senior Vice President, Clinical Development
- Kenji Iizuka, PhD – Vice President, Pharmaceutical Development
The company is governed by a board of directors with backgrounds in biotechnology, finance, and drug development, consistent with its focus on advancing late-stage clinical assets toward potential commercialization.